Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Protagonist Therapeutics Inc. (PTGX)

NASDAQ: PTGX · Pharmaceutical Preparations · Newark, CA

Our rating: Neutral

Neutral reaffirmed at $135.90, moderate conviction, November 9, 2026.

Breaks if: The Neutral call turns Cautious if reported free cash flow goes negative in any of the next two quarterly filings, or if the trailing net loss widens beyond $200M without a disclosed ramp in revenue — either condition would mean the cash-generation story is unwinding. It turns Positive if FCF reaches $130M or above within four quarters and the company discloses a revenue line showing year-on-year growth, confirming the commercial or partnership engine is genuinely scaling rather than front-loaded.

Key figures

Market value$7.9B
Revenue, last 12 months$552M
Net income, last 12 months$342M
Free cash flow, last 12 months$109M
Price to earnings23.2×
Free cash flow yield1.4%
Dividend yield0.0%
Operating margin58.6%
Return on equity39.6%
Beta to the S&P 5000.37
Volatility, annualized55.2%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$274M5723.6%$3.07−$23M
June 30, 2026$213M3749.2%$2.29$219M
March 31, 2026$56M99.0%$0.05−$49M
December 31, 2025$7M−95.6%$-0.70−$37M
September 30, 2025$5M0.8%$-0.62−$2M
June 30, 2025$6M33.1%$-0.55−$30M
March 31, 2025$28M−88.9%$-0.19$125M
December 31, 2024$171M184.4%$2.01−$29M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

12 ledger entries and 32 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.